MITech Acquisitions

  •  07/01/2016 – MITech acquires Decatur Health Imaging, LLC an independent outpatient diagnostic testing facility providing outpatient PET/CT imaging scans.
  • 08/07/2015 – MITech acquires Affiliated PET Systems, LLC an independent outpatient diagnostic testing facility providing outpatient PET/CT and Diagnostic CT imaging scans.
  • 04/17/2015 – MITech acquires Oncology Molecular Imaging, LLC comprised of 5 outpatient PET/CT imaging centers.

MITech Clinical Trials/Research News

  • 01/2018 – MITech locations awarded a 3-year term of accreditation by the American College of Radiology (“ACR”). The ACR gold seal of accreditation represents the highest level of image quality and patient safety. It is awarded only to facilities meeting ACR Practice Parameters and Technical Standards after a peer-review evaluation by board-certified physicians and medical physicists who are experts in the field. Image quality, personnel qualifications, adequacy of facility equipment, quality control procedures and quality assurance programs are assessed.
  • 01/2018 – MITech to begin Using Ga-68 DOTATATE FDA approved new diagnostic imaging agent to detect rare neuroendocrine tumors. 68Ga-DOTATATE PET/CT has demonstrated superiority in lesion detection compared to Octreoscan, MIBG scintigraphy and MRI.
  • 2017/2018 – MITech participating in various Neurology clinical trials for Alzheimer’s, Dementia, and Tau proteins. BIOGEN 221AD301/221AD302 TAU SUB-STUDY; ROCHE CREAD BN29553; ROCHE GRADUATE 1 STUDY WN29922; I8D-MC-AZET; H8A-MC-LZBE; 17X-MC-LLCF; EISAI E2609-G000-301; EISAI E2609-G000-302; BIOGEN 221AD301.
  • 02/2017 – MITech begins performing PET/CT imaging with Axumin™ (fluciclovine F 18) injection which is indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment.
  • 2017 – MITech participating in TARGET Trial to help determine if rheumatoid arthritis patients are in remission after treatment.
  • 03/2016 – MITech featured on 6ABC news for implementing clinical research trials for Alzheimer’s Disease at Philadelphia, PA location.
  • 01/2016 – MITech launches the Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) Study. The 3 isotopes approved for the study are Neuraceq, Amyvid, and Vizamyl. The IDEAS Study will focus on brain images called amyloid PET scans which can show if amyloid plaques are building up in the brain. The presence or absence of amyloid plaques will help doctor’s determine the likelihood that patient’s symptoms are caused by Alzheimer’s disease.
  • 11/2015 – MITech approved by Molecular NeuroImaging LLC and Institute for Neurodegenerative Disorders to be used for the Eli Lilly LZAX study for the Effect of Passive Immunization on the Progression of Mild Alzheimer’s Disease: Solanezumab (LY2062430) Versus Placebo.
  • 2015 – MITech participating in TRx-237-005 and EISAI BAN 2401-G000-201 Neurology clinical trials for Alzheimer’s and Dementia.
  • 09/2012 – Molecular Imaging Technologies, LLC to Begin Using Amyvid® to Rule Out Alzheimer’s Disease.

MITech begins to offer Amyvid® for PET/CT imaging of the brain to identify the presence of plaque in the brain, which has been shown to be a precursor to Alzheimer’s Disease (AD) and other causes of cognitive decline.

Amyvid® is a radioactive diagnostic agent for PET imaging of the brain to estimate beta-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s Disease and other causes of cognitive decline. A negative Amyvid® scan indicates sparse to no neuritic plaques and is inconsistent with a neuropathological diagnosis of Alzheimer’s Disease at the time of image acquisition; a negative scan result reduces the likelihood that a patient’s cognitive impairment is due to Alzheimer’s Disease. A positive Amyvid® scan indicates moderate to frequent amyloid neuritic plaques; neuropathological examination has shown this amount of amyloid neuritic plaque is present in patients with Alzheimer’s Disease, but may also be present in patients with other types of neurologic conditions as well as older people with normal cognition. Amyvid® is an adjunct to other diagnostic evaluations.

  • 2011 – MITech begins participation in the NOPR for Sodium Fluoride (NaF-18) which is a highly sensitive bone seeking PET tracer used for detection of skeletal abnormalities. The uptake mechanism is similar to Tc-99m MDP, but with better physical characteristics for imaging.